Progress and Prospects in Oncolytic Virotherapy

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Human Virology and Viral Diseases".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 273

Special Issue Editors

Department of Molecular Medicine, University of Padua, Padova, Italy
Interests: virus–host interactions; viral vectors; oncovirotherapy; antiviral strategies
Gynaecological Oncology, KU Leuven, 3000 Leuven, Belgium
Interests: cancer immunology and immunotherapy; tumor antigens; drug repurposing

Special Issue Information

Dear Colleagues,

Oncovirotherapy is a very promising strategy to tackle tumors based on viruses that either naturally or upon specific manipulations display direct cancer-cell-killing activity along with immunotherapeutic effects. Although a growing number of clinical studies clearly demonstrate the excellent safety profile of oncolytic viruses, to date, only the HSV-1 talimogene laherparepvec (T-Vec) has been approved in the USA and Europe for the treatment of unresectable melanoma. One of the reasons for the limited approval of oncolytic viruses can be found in their adoption as monotherapy in most of the clinical trials performed so far, often resulting in poor efficacy. This Special Issue aims to present readers with the latest developments and challenges in the field of oncolytic virus research. Additionally, we aim to evaluate the therapeutic possibilities of integrating oncovirotherapy with chemotherapy or immunotherapy.

Dr. Arianna Calistri
Dr. Sandra Tuyaerts
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oncovirotherapy
  • chemotherapy
  • preclinical studies
  • clinical trials
  • combinatory strategy
  • safety profile
  • therapeutic efficacy
  • immunotherapy

Published Papers

This special issue is now open for submission.
Back to TopTop